{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:19:02Z","timestamp":1787613542143,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-025-00887-9","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:44:03Z","timestamp":1780026243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)\/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results"],"prefix":"10.1038","volume":"12","author":[{"given":"Meritxell","family":"Bellet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Ferrero-Cafiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milana","family":"Bergamino Sirv\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudette","family":"Falato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kepa.","family":"Amillano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Chic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafin","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Gasol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nuciforo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Villagrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline H.","family":"Diep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Seelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Assoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"887_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-017-0462-7","volume":"10","author":"TP Knutson","year":"2017","unstructured":"Knutson, T. P. et al. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. J. Hematol. Oncol. 10, 89 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"887_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0959-8049(98)00388-8","volume":"35","author":"JFR Robertson","year":"1999","unstructured":"Robertson, J. F. R., Willsher, P. C., Winterbottom, L., Blamey, R. W. & Thorpe, S. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur. J. Cancer 35, 214\u2013218 (1999).","journal-title":"Eur. J. Cancer"},{"key":"887_CR3","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.1996.14.10.2709","volume":"14","author":"D Perrault","year":"2025","unstructured":"Perrault, D. et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 14, 2709\u20132712 (2025).","journal-title":"J. Clin. Oncol."},{"key":"887_CR4","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1093\/annonc\/mdt216","volume":"24","author":"W Jonat","year":"2013","unstructured":"Jonat, W. et al. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann. Oncol. 24, 2543\u20132548 (2013).","journal-title":"Ann. Oncol."},{"key":"887_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1078-0432.CCR-19-0443","volume":"26","author":"O Lee","year":"2020","unstructured":"Lee, O. et al. Selective progesterone receptor modulators in early-stage breast cancer: a randomized, placebo-controlled phase II window-of-opportunity trial using telapristone acetate. Clin. Cancer Res. 26, 25\u201334 (2020).","journal-title":"Clin. Cancer Res."},{"key":"887_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/1078-0432.CCR-22-2060","volume":"29","author":"A El\u00eda","year":"2023","unstructured":"El\u00eda, A. et al. Beneficial effects of mifepristone treatment in patients with breast cancer selected by the progesterone receptor isoform ratio: results from the MIPRA Trial. Clin. Cancer Res. 29, 866\u2013877 (2023).","journal-title":"Clin. Cancer Res."},{"key":"887_CR7","doi-asserted-by":"publisher","first-page":"e0204973","DOI":"10.1371\/journal.pone.0204973","volume":"13","author":"PH Cottu","year":"2018","unstructured":"Cottu, P. H. et al. Phase i study of onapristone, a type i antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. PLoS ONE 13, e0204973 (2018).","journal-title":"PLoS ONE"},{"key":"887_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40264-020-00964-x","volume":"43","author":"JH Lewis","year":"2020","unstructured":"Lewis, J. H. et al. Onapristone extended release: safety evaluation from phase I\u2013II studies with an emphasis on hepatotoxicity. Drug Saf. 43, 1045\u20131055 (2020).","journal-title":"Drug Saf."},{"key":"887_CR9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. JCO 36, 2105\u20132122 (2018).","journal-title":"JCO"},{"key":"887_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update. Arch. Pathol. Lab. Med. 144, 545\u2013563 (2020).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"887_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/jnci\/djab057","volume":"114","author":"N Chic","year":"2022","unstructured":"Chic, N. et al. Tumor cellularity and infiltrating lymphocytes as a survival surrogate in HER2-positive breast cancer. J. Natl. Cancer Inst. 114, 467\u2013470 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"887_CR12","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-16-2092","volume":"23","author":"A Prat","year":"2017","unstructured":"Prat, A. et al. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse. Clin. Cancer Res. 23, 3035\u20133044 (2017).","journal-title":"Clin. Cancer Res."},{"key":"887_CR13","doi-asserted-by":"crossref","unstructured":"Hagan, C. R. & Lange, C. A. Molecular Determinants of Context-Dependent Progesterone Receptor Action in Breast Cancer. http:\/\/www.biomedcentral.com\/1741-7015\/12\/32.","DOI":"10.1186\/1741-7015-12-32"},{"key":"887_CR14","unstructured":"Lange, C. A., Shen, T. & Horwitz, K. B. Phosphorylation of Human Progesterone Receptors at Serine-294 by Mitogen-Activated Protein Kinase Signals Their Degradation by the 26S Proteasome. www.pnas.org."},{"key":"887_CR15","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1128\/MCB.21.18.6122-6131.2001","volume":"21","author":"T Shen","year":"2001","unstructured":"Shen, T., Horwitz, K. B. & Lange, C. A. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell. Biol. 21, 6122\u20136131 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"887_CR16","doi-asserted-by":"publisher","first-page":"10542","DOI":"10.1128\/MCB.24.24.10542-10557.2004","volume":"24","author":"LK Pierson-Mullany","year":"2004","unstructured":"Pierson-Mullany, L. K. & Lange, C. A. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol. Cell. Biol. 24, 10542\u201310557 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"887_CR17","unstructured":"Daniel, A. R., Lange, C. A. & O\u2019malley, B. W. Protein Kinases Mediate Ligand-Independent Derepression of Sumoylated Progesterone Receptors in Breast Cancer Cells. www.pnas.org\/cgi\/content\/full\/."},{"key":"887_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-0527-z","volume":"18","author":"J Ma","year":"2020","unstructured":"Ma, J., Qin, L. & Li, X. Role of STAT3 signaling pathway in breast cancer. Cell Commun. Signal. 18, 33 (2020).","journal-title":"Cell Commun. Signal."},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"38886","DOI":"10.1074\/jbc.M111.286245","volume":"286","author":"M Snyder","year":"2011","unstructured":"Snyder, M., Huang, X.-Y. & Zhang, J. J. Signal Transducers and Activators of Transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J. Biol. Chem. 286, 38886\u201338893 (2011).","journal-title":"J. Biol. Chem."},{"key":"887_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/stem.1609","volume":"32","author":"G Huang","year":"2014","unstructured":"Huang, G., Yan, H., Ye, S., Tong, C. & Ying, Q. L. STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates mouse esc fates. Stem Cells 32, 1149\u20131160 (2014).","journal-title":"Stem Cells"},{"key":"887_CR21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1210\/en.2018-00990","volume":"160","author":"TH Truong","year":"2019","unstructured":"Truong, T. H. et al. Phosphorylated progesterone receptor isoforms mediate opposing stem cell and proliferative breast cancer cell fates. Endocrinology 160, 430\u2013446 (2019).","journal-title":"Endocrinology"},{"key":"887_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/clinem\/dgab195","volume":"106","author":"LJ Mauro","year":"2021","unstructured":"Mauro, L. J. et al. Progesterone receptors promote quiescence and ovarian cancer cell phenotypes via DREAM in p53-Mutant fallopian tube models. J. Clin. Endocrinol. Metab. 106, 1929\u20131955 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/JTO.0b013e3181d5e554","volume":"5","author":"HJ Lee","year":"2010","unstructured":"Lee, H. J. et al. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (Seventh) New TNM classification. J. Thorac. Oncol. 5, 649\u2013657 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"887_CR24","doi-asserted-by":"publisher","first-page":"e0165253","DOI":"10.1371\/journal.pone.0165253","volume":"11","author":"Y Horimoto","year":"2016","unstructured":"Horimoto, Y. et al. Combination of cancer stem cell markers CD44 and CD24 is superior to ALDH1 as a prognostic indicator in breast cancer patients with distant metastases. PLoS ONE 11, e0165253 (2016).","journal-title":"PLoS ONE"},{"key":"887_CR25","doi-asserted-by":"publisher","first-page":"e0206685","DOI":"10.1371\/journal.pone.0206685","volume":"13","author":"H-H Huang","year":"2018","unstructured":"Huang, H.-H., Wang, Y.-C., Chou, Y.-C., Yu, M.-H. & Chao, T.-K. The combination of aldehyde dehydrogenase 1 (ALDH1) and CD44 is associated with poor outcomes in endometrial cancer. PLoS ONE 13, e0206685 (2018).","journal-title":"PLoS ONE"},{"key":"887_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00404-023-06996-9","volume":"309","author":"M Zwahlen","year":"2023","unstructured":"Zwahlen, M. & Stute, P. Impact of progesterone on the immune system in women: a systematic literature review. Arch. Gynecol. Obstet. 309, 37\u201346 (2023).","journal-title":"Arch. Gynecol. Obstet."},{"key":"887_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0911-9","volume":"19","author":"HO Ohnstad","year":"2017","unstructured":"Ohnstad, H. O. et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res. 19, 120 (2017).","journal-title":"Breast Cancer Res."},{"key":"887_CR28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"PS Bernard","year":"2009","unstructured":"Bernard, P. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol."},{"key":"887_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/BF01236387","volume":"120","author":"Y Nishino","year":"1994","unstructured":"Nishino, Y., Schneider, M. R. & Michna, H. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384. J. Cancer Res. Clin. Oncol. 120, 298\u2013302 (1994).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"887_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.clbc.2024.11.019","volume":"25","author":"S Kamaraju","year":"2025","unstructured":"Kamaraju, S. et al. A phase II trial of onapristone and fulvestrant for patients with ER+ and HER2- metastatic breast cancer. Clin. Breast Cancer 25, 251\u2013260 (2025).","journal-title":"Clin. Breast Cancer"},{"key":"887_CR31","doi-asserted-by":"publisher","first-page":"e001710","DOI":"10.1136\/jitc-2020-001710","volume":"9","author":"LR Werner","year":"2021","unstructured":"Werner, L. R. et al. Progesterone promotes immunomodulation and tumor development in the murine mammary gland. J. Immunother. Cancer 9, e001710 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"887_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep29434","volume":"6","author":"DA Pearce","year":"2016","unstructured":"Pearce, D. A. et al. Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies. Sci. Rep. 6, 29434 (2016).","journal-title":"Sci. Rep."},{"key":"887_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jncics\/pky005","volume":"2","author":"Q Gao","year":"2018","unstructured":"Gao, Q. et al. Major impact of sampling methodology on gene expression in estrogen receptor\u2013positive breast cancer. JNCI Cancer Spectr. 2, 1\u20134 (2018).","journal-title":"JNCI Cancer Spectr."},{"key":"887_CR34","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline Update. J. Clin. Oncol. 38, 1346\u20131366 (2020).","journal-title":"J. Clin. Oncol."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00887-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00887-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00887-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:33:44Z","timestamp":1787610824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00887-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1038\/s41523-025-00887-9","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Meritxell Bellet has declared an advisor role or consulting from Novartis, Pfizer, Lilly, Stemline Menarini and travel expenses from Pfizer and Roche. Milana Bergamino has declared an advisor role or consulting fees from Lilly Eli, Pfizer, Novartis, Daiichi Sankyo and Astra Zeneca and travel expenses from Novartis and Astra Zeneca. She also declares salary from Fundaci\u00f3n BBVA grant Joan Rod\u00e9s-Josep Baselga 2024-2027. Claudette Falato has been employed by AstraZeneca since September 2023, however involvement in this study predates this employment and AstraZeneca was not involved in the study. Tom\u00e1s Pascual reports having received Fees for Non-CME Services Received Directly from Commercial Interest ortheir Agents (e.g., speakers' bureaus) from Astra Zeneca, Consulting Fees (e.g., advisory boards) from Novartis, andFees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) from Pfizer. Xavier Gonzalez-Farr\u00e9 has declared personal honoraria from Astra Zeneca, Pierre Fabre, Novartis, Roche and travelexpenses from Astra Zeneca, Roche, Lilly Aleix Prat has declared personal honoraria from Pfizer, Novartis, Roche, Reveal Genomics, Lilly and Daiichi Sankyo, travel, accommodations, and expenses paid by Daiichi Sankyo, research funding from Roche, AstraZeneca, RevealGenomics and Novartis, consulting\/advisory role for Reveal Genomics, Roche, Novartis, Pfizer, and Daiichi Sankyo,Inc. outside the submitted work. Cristina Saura has declared personal honoraria as consulting\/advisory from AstraZeneca, AX'Consulting, Byondis B.V, Daiichi Sankyo, Eisai, Exact Sciences, Exeter Pharma, F.Hoff mann-La Roche Ltd, Lilly, MediTech, Merck Sharp & Dohme, Novartis, Pfizer, Philips, Pierre Fabre, PintPharma, Puma Biotechnology, SeaGen, and Zymeworks. The other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"110"}}